Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13589890 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL21307962 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL29484643 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Fumaric Acid SCHEMBL29615612 | 0.91 | CHRNB2 (0.82) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL397542 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL21308152 | 0.82 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL30534203 | 0.81 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL12102742 | 0.81 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL16431875 | 0.74 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 | |
| SCHEMBL25658 | 0.67 | CHRNA7 (0.71) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117907482-A | Tandem solid phase extraction-liquid chromatography-tandem mass spectrometry detection method for simultaneously determining four types of cyanobacteria toxins in water body | 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） | 2024-04-19 | — | — | CN | claimed |
| WO-2023012796-A1 | A CELL-BASED METHOD FOR DETECTING POTENTIALLY PATHOGENIC AUTOANTIBODIES TO NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | TZARTOS NEURODIAGNOSTICS (GR) | 2023-02-09 | — | — | WO | claimed |
| CN-115200968-A | Method for purifying various cyanobacteria toxins from algal bloom water body | 深圳市环境科学研究院 | 2022-10-18 | — | — | CN | claimed |
| US-11414329-B2 | Treatment of cyanotoxin-containing water | EVONIK OPERATIONS GMBH (DE) | 2022-08-16 | — | — | US | claimed |
| WO-2022009207-A1 | METHODS OF TREATING COVID-19 USING CHOLINERGIC AGONISTS, MODIFIED ANTIBODIES AND NASOPHARYNGEAL WASH | FARSALINOS KONSTANTINOS (GR) | 2022-01-13 | — | — | WO | claimed |
| US-11125750-B2 | Methods, assays and kits for detecting exposure to cyanotoxins | THE UNIVERSITY OF TOLEDO (US) | 2021-09-21 | — | — | US | claimed |
| US-11054415-B2 | Preparation of bioconjugates and antibodies for the immunodetection of anatoxin-a | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2021-07-06 | — | — | US | claimed |
| EP-3752466-A1 | TREATMENT OF CYANOTOXIN-CONTAINING WATER | PeroxyChem LLC (US) | 2020-12-23 | — | — | EP | claimed |
| US-10641769-B1 | Rapid analysis for cyanobacterial toxins | ABRAXIS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| US-10444217-B1 | Rapid analysis for cyanobacterial toxins | ABRAXIS, INC. (US) | 2019-10-15 | — | — | US | claimed |
| US-20190265233-A1 | PREPARATION OF BIOCONJUGATES AND ANTIBODIES FOR THE IMMUNODETECTION OF ANATOXIN-A | UNIVERSITAT DE VALÈNCIA (ES) | 2019-08-29 | — | — | US | claimed |
| US-20190248679-A1 | TREATMENT OF CYANOTOXIN-CONTAINING WATER | PEROXYCHEM LLC (US) | 2019-08-15 | — | — | US | claimed |
| US-10338067-B1 | Rapid analysis for cyanobacterial toxins | ABRAXIS, INC. (US) | 2019-07-02 | — | — | US | claimed |
| US-9739777-B1 | Rapid analysis for cyanobacterial toxins | Abraxis Inc. (US) | 2017-08-22 | — | — | US | claimed |
| EP-4735609-A2 | COMPOSITIONS, CONSTRUCTS, PLANT VIRAL VECTORS, AND METHODS FOR PLANT GENE EDITING | The Regents of the University of California (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3359085-B1 | CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES | TOTH LANDY (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250346503-A1 | SYNERGISTIC GREEN SORPTION MEDIA FOR CYANOBACTERIAL TOXIN REMEDIATION | UNIV CENTRAL FLORIDA RES FOUND INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-5482938-A | Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| US-5346911-A | Analgesics, cognition activators, treatment of alzheimer*s s disease | WARNER-LAMBERT COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0445731-A1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190265233-A1 | PREPARATION OF BIOCONJUGATES AND ANTIBODIES FOR THE IMMUNODETECTION OF ANATOXIN-A | INHA, ANTXR2, INA | CHRNB2 75/4885CHRNA4 64/4885CHRNA7 27/4885 |
| US-11054415-B2 | Preparation of bioconjugates and antibodies for the immunodetection of anatoxin-a | INHA, ANTXR2, INA | CHRNB2 75/4885CHRNA4 64/4885CHRNA7 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.